Fortunately, reality is not the same, nor similar, to which it was lived in the 80s, with the irruption of the HIV. Disinformation is no longer a weapon of virusresearch has taken giant in these years and the perception of this pandemia He has begun to put aside the stigma he meant at that time.
Although the figures remain worrying, with an average of 3,000 new diagnoses per year During the last decade, the truth is that the trend progresses down.
The studies have not ceased in these years and today we focus on a kind of vaccine that would mean a very valuable tool in the prevention of said infection. We talk about lenacapaviran injectable antiviral medication that offers great hopes in the prevention of HIV-1.
Carlos Fernández MorianoResponsible for scientific dissemination of the General College of Pharmacists, explains how this active substance has already been approved by the European Commission.
What Lenacapavir does is inhibit the function of the capsid of the Del VIH virus And with that inhibition it is prevented that this virus be replicated in our body and, therefore, that the infection occurs or perpetuated.
Who is it directed to?
It is not an unknown active substance, Fernández Moriano explains that “initially arrived last year to Spain in another medicine, with another commercial name, with the authorization in the treatment of HIV infections that are multirresistant. Now, this new medicine has been approved at the EU level for the Pre-exposure prophylaxis which is an administration pattern for the prevention of groups in groups.
“Indeed, today is the medication with Lenacapavir that is used at the hospital level, but steps are being taken for these medications to get out of the hospital, which can be available in community pharmacies For those prevention purposes. The treatment would go another way, “says this expert.
In addition to its efficacy for prevention, Lenacapavir is an advance in the pattern, since now preventive treatments imply the administration of a daily pill, while this would be an injection every 6 months.
Fear that the guard gets off
We ask Carlos Fernández if this “tool” cannot cause a negative effect, if patients believe they are protected and They lower their guard With other protection shields. His answer is clear: “There is the key, in that health education work that all health professionals must carry out. The fact that we have vaccinated, than Let’s be taking something as a preventiveit does not have to relax and think that we are already free of risk. In addition, there is no 100% protection with this medicine, there is always some risk and, therefore, that indication must be associated with safer sexual practices, precisely what needs to be done is to influence that we do not forget other preventive measures, not only by HIV infection but of other sexually transmitted infections. “
On August 26, Brussels gave his approval so that Gilead Yeytuo deployment Among the 27 member countries of the European Union. Yeytuo is the name with which the medicine will be marketed with this active substance. The treatment includes two injectables per year that would work as pre-exposure prophylaxis and that would be administered to seronegative people to prevent infection. Studies show a Effectiveness of 99.9%.
Last Thursday, the Spanish Agency for Medicines and Health Products He confirmed that the work for the therapeutic positioning reports of this drug had already started. The agency assigned to the Ministry of Health will begin to evaluate the effectiveness, safety, cost-effectivity and impact on health.
Follow us in our WhatsApp channel and do not miss the last hour and all the actuality of antena3noticias.com.
